Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib

Por Lemos, C, Kathmann, I, Giovannetti, E, Calhau, C, Jansen, G, Peters, G J
Publicado em 2009

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Por Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E
Publicado em 2016-10-01

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile

Por Giovannetti, E, Mey, V, Danesi, R, Basolo, F, Barachini, S, Deri, M, Del Tacca, M
Publicado em 2005

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Por Tekle, C, Giovannetti, E, Sigmond, J, Graff, J R, Smid, K, Peters, G J
Publicado em 2008

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

Por Mey, V, Giovannetti, E, Braud, F De, Nannizzi, S, Curigliano, G, Verweij, F, De Cobelli, O, Pece, S, Del Tacca, M, Danesi, R
Publicado em 2006

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia

Por Maftouh, M, Avan, A, Sciarrillo, R, Granchi, C, Leon, L G, Rani, R, Funel, N, Smid, K, Honeywell, R, Boggi, U, Minutolo, F, Peters, G J, Giovannetti, E
Publicado em 2014

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

Por Giovannetti, E, Backus, H H J, Wouters, D, Ferreira, C G, van Houten, V M M, Brakenhoff, R H, Poupon, M-F, Azzarello, A, Pinedo, H M, Peters, G J
Publicado em 2007

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

Por Bengala, C, Guarneri, V, Giovannetti, E, Lencioni, M, Fontana, E, Mey, V, Fontana, A, Boggi, U, Del Chiaro, M, Danesi, R, Ricci, S, Mosca, F, Del Tacca, M, Conte, P F
Publicado em 2005

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

Por Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
Publicado em 2011

Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD

Por Dickerson, B.C., Salat, D.H., Greve, D.N., Chua, E.F., Rand-Giovannetti, E., Rentz, D.M., Bertram, L., Mullin, K., Tanzi, R.E., Blacker, D., Albert, M.S., Sperling, R.A.
Publicado no Neurology (2005)